Concepedia

Marco V. Haselager

MV

Statistics

Publications

5

Citations

273

H-Index

5

Active since

2020

Affiliations

University of Amsterdam(Current)

Amsterdam University Medical Centers

Cancer Center Amsterdam

Institute of Infection and Immunity

University of Strathclyde

Marco V. Haselager is an author at University of Amsterdam specializing in life sciences, bcl-2 family proteins, and cell biology.

ORCID

Publications per year

2020–2023

5

Publications

5

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

Marco V. Haselager, Karoline Kielbassa, Johanna ter Burg et al. · Blood · 2020 · 116 citations · Full text

, , +14

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL

Marco V. Haselager, Rachel Thijssen, Christopher M. West et al. · Cell Death and Differentiation · 2021 · 87 citations · Full text

, , +13

<scp>JAK–STAT</scp> signalling shapes the <scp>NF‐κB</scp> response in <scp>CLL</scp> towards venetoclax sensitivity or resistance via <scp>Bcl‐XL</scp>

Marco V. Haselager, Rachel Thijssen, Danique Bax et al. · Molecular Oncology · 2022 · 26 citations · Full text

, , +16

In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival

Marco V. Haselager, Bianca F. van Driel, Eduard Perelaer et al. · HemaSphere · 2023 · 24 citations · Full text

, , +17

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

Karoline Kielbassa, Marco V. Haselager, Danique Bax et al. · Leukemia · 2023 · 20 citations · Full text

, , +17

1–5 of 5